Abstract CT222: Phase Ib/II study of fruquintinib (F) combined with capecitabine (C) as maintenance therapy (MT) for RAS/BRAF wild-type metastatic colorectal cancer (mCRC) after first-line treatment with cetuximab combined with chemotherapy - KIVIRID

Abstract CT222: Phase Ib/II study of fruquintinib (F) combined with capecitabine (C) as maintenance therapy (MT) for RAS/BRAF wild-type metastatic colorectal cancer (mCRC) after first-line treatment with cetuximab combined with chemotherapy

Authors: Kai Ou, Biyang Cao, Wenwei Yang, Letian Zhang, Jingyu Lu, Lin Yang

Published: 2025-04-25

DOI: 10.1158/1538-7445.am2025-ct222

Source: Full article

Abstract

Abstract